FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895933119> ?p ?o ?g. }

• W2895933119 endingPage "116" @default.
• W2895933119 startingPage "108" @default.
• W2895933119 abstract "Aim of the study The optimal therapeutic strategy in patients with rectal cancer and synchronous unresectable metastases remains unknown. We evaluated the efficacy of FOLFIRINOX induction therapy in this setting. Patients and methods Chemotherapy-naïve patients received at least 8 cycles of FOLFIRINOX. The primary end-point was the 4-month disease control (4 m DC) rate. Tumour responses were centrally reviewed and assessed by computed tomography scan for metastases (Response Evaluation Criteria in Solid Tumours criteria) and magnetic resonance imaging for rectal tumorus. With a Simon 2-stage design and a targeted (H1) 4 m DC > 75%, 65 patients were enrolled from July 2012 to February 2015: male, 78%; median age, 61 years; performance status, 0–1, 98%; liver metastases, 92%; ≥2 metastatic sites, 63%. Results Fifty-six (85%) of the 65 patients received the 8 planned FOLFIRINOX cycles. The primary objective was achieved (4 m DC rate: 94%; 95% confidence interval [CI], 86.3–97.8). Primary tumour symptoms decreased from 72% at baseline to 10% at 4 months. Response rate was 86%, and a >70% primary tumour volume decrease was seen in 63% of patients. Forty-four patients (68%) had at least one grade 3 side-effect; no toxic deaths occurred. Median follow-up was 35.0 months (95% CI, 31.3–43.7). Median progression-free survival and overall survival were 10.9 m (95% CI, 8.8–12.9) and 33.4 m (95% CI, 22.6–38.2), respectively. Conclusion Upfront FOLFIRINOX is feasible and allows good local and distant control. It therefore offers the opportunity to choose the best therapeutic strategy for each patient and to personalise treatment according to the local and distant efficacy results of this induction step. Trial registration Clinicaltrials.gov, NCT01674309." @default.
• W2895933119 created "2018-10-26" @default.
• W2895933119 creator A5004345561 @default.
• W2895933119 creator A5018589423 @default.
• W2895933119 creator A5019977580 @default.
• W2895933119 creator A5020520466 @default.
• W2895933119 creator A5028514396 @default.
• W2895933119 creator A5028824489 @default.
• W2895933119 creator A5030009461 @default.
• W2895933119 creator A5032193447 @default.
• W2895933119 creator A5036106894 @default.
• W2895933119 creator A5037416771 @default.
• W2895933119 creator A5043228759 @default.
• W2895933119 creator A5043463827 @default.
• W2895933119 creator A5045766264 @default.
• W2895933119 creator A5046581053 @default.
• W2895933119 creator A5047740666 @default.
• W2895933119 creator A5049363884 @default.
• W2895933119 creator A5053516761 @default.
• W2895933119 creator A5058465685 @default.
• W2895933119 creator A5061710022 @default.
• W2895933119 creator A5070237613 @default.
• W2895933119 creator A5073835004 @default.
• W2895933119 creator A5076309223 @default.
• W2895933119 creator A5076574340 @default.
• W2895933119 creator A5084815041 @default.
• W2895933119 creator A5086835459 @default.
• W2895933119 creator A5087845861 @default.
• W2895933119 date "2018-11-01" @default.
• W2895933119 modified "2023-10-17" @default.
• W2895933119 title "FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial" @default.
• W2895933119 cites W1993780950 @default.
• W2895933119 cites W1994304596 @default.
• W2895933119 cites W1996131773 @default.
• W2895933119 cites W2005348280 @default.
• W2895933119 cites W2030140843 @default.
• W2895933119 cites W2032673576 @default.
• W2895933119 cites W2086501373 @default.
• W2895933119 cites W2103274794 @default.
• W2895933119 cites W2106845199 @default.
• W2895933119 cites W2107710830 @default.
• W2895933119 cites W2111837783 @default.
• W2895933119 cites W2115153468 @default.
• W2895933119 cites W2116866881 @default.
• W2895933119 cites W2118571739 @default.
• W2895933119 cites W2120520892 @default.
• W2895933119 cites W2124886112 @default.
• W2895933119 cites W2129998117 @default.
• W2895933119 cites W2132565869 @default.
• W2895933119 cites W2133399075 @default.
• W2895933119 cites W2136219014 @default.
• W2895933119 cites W2167845292 @default.
• W2895933119 cites W2298062036 @default.
• W2895933119 cites W2415398359 @default.
• W2895933119 cites W2470575266 @default.
• W2895933119 cites W2513739777 @default.
• W2895933119 doi "https://doi.org/10.1016/j.ejca.2018.09.006" @default.
• W2895933119 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30343254" @default.
• W2895933119 hasPublicationYear "2018" @default.
• W2895933119 type Work @default.
• W2895933119 sameAs 2895933119 @default.
• W2895933119 citedByCount "16" @default.
• W2895933119 countsByYear W28959331192019 @default.
• W2895933119 countsByYear W28959331192020 @default.
• W2895933119 countsByYear W28959331192021 @default.
• W2895933119 countsByYear W28959331192022 @default.
• W2895933119 countsByYear W28959331192023 @default.
• W2895933119 crossrefType "journal-article" @default.
• W2895933119 hasAuthorship W2895933119A5004345561 @default.
• W2895933119 hasAuthorship W2895933119A5018589423 @default.
• W2895933119 hasAuthorship W2895933119A5019977580 @default.
• W2895933119 hasAuthorship W2895933119A5020520466 @default.
• W2895933119 hasAuthorship W2895933119A5028514396 @default.
• W2895933119 hasAuthorship W2895933119A5028824489 @default.
• W2895933119 hasAuthorship W2895933119A5030009461 @default.
• W2895933119 hasAuthorship W2895933119A5032193447 @default.
• W2895933119 hasAuthorship W2895933119A5036106894 @default.
• W2895933119 hasAuthorship W2895933119A5037416771 @default.
• W2895933119 hasAuthorship W2895933119A5043228759 @default.
• W2895933119 hasAuthorship W2895933119A5043463827 @default.
• W2895933119 hasAuthorship W2895933119A5045766264 @default.
• W2895933119 hasAuthorship W2895933119A5046581053 @default.
• W2895933119 hasAuthorship W2895933119A5047740666 @default.
• W2895933119 hasAuthorship W2895933119A5049363884 @default.
• W2895933119 hasAuthorship W2895933119A5053516761 @default.
• W2895933119 hasAuthorship W2895933119A5058465685 @default.
• W2895933119 hasAuthorship W2895933119A5061710022 @default.
• W2895933119 hasAuthorship W2895933119A5070237613 @default.
• W2895933119 hasAuthorship W2895933119A5073835004 @default.
• W2895933119 hasAuthorship W2895933119A5076309223 @default.
• W2895933119 hasAuthorship W2895933119A5076574340 @default.
• W2895933119 hasAuthorship W2895933119A5084815041 @default.
• W2895933119 hasAuthorship W2895933119A5086835459 @default.
• W2895933119 hasAuthorship W2895933119A5087845861 @default.
• W2895933119 hasConcept C121608353 @default.
• W2895933119 hasConcept C126322002 @default.
• W2895933119 hasConcept C126838900 @default.
• W2895933119 hasConcept C141071460 @default.

• next